NASDAQ · XENE

Xenon Pharmaceuticals Inc.

$65.42 $0.00 (+0.00%) 1D After hours

Key Metrics

$6.32B
Market cap
P/E · TTM
Revenue · TTM
−$383.17M
Net income
EPS · TTM $-4.87
Dividend yield
Free cash flow −$307.25M
Beta · 1Y 0.66
EBITDA · TTM
Gross margin

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Jul 8
    The stock moved +10.4% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jul 8
  • Mar 9
    The stock moved +49.6% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Mar 9

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$6.32B
Enterprise value
Shares outstanding96.7M
52-wk range$30.00 – $72.66
Avg volume · 20D633.8K
Net cash
Book value / share$17.00
IndustryPharmaceutical Preparations
ExchangeNASDAQ
About Xenon Pharmaceuticals Inc.
IPO dateNov 5, 2014
Employees370

Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S
P/FCF
EV/EBITDA
EV/Sales
Graham №

Profitability

Gross
Operating
Net
FCF
ROE / ROIC -36.6% · -157.6%

Financial Health

Current ratio27.79
Quick ratio
Debt / equity
Debt / EBITDA
Net cash
Working capital$1.07B

Cash Flow · TTM

Operating CF −$306.36M
Capex −$889.00K
Free cash flow −$307.25M
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

1 / 9
Weak fundamentals · 1 of 9 signals passing

Altman Z-Score

Insufficient balance-sheet inputs

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings